KRAS G12C LUNG CANCER

Clinical trials for KRAS G12C LUNG CANCER explained in plain language.

Never miss a new study

Get alerted when new KRAS G12C LUNG CANCER trials appear

Sign up with your email to follow new studies for KRAS G12C LUNG CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1 Not yet recruiting 1 Not yet finished but already full! 1

Breakthrough trial targets deadly lung cancer mutation with new drug combo

Disease control Recruiting now

This study compares a new two-drug combination (divarasib + pembrolizumab) against standard chemotherapy for adults with advanced lung cancer that has a specific KRAS G12C mutation and hasn't been treated before. The goal is to see if the new combination helps patients live longe…

Matched conditions: KRAS G12C LUNG CANCER

Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control

Last updated Mar 30, 2026 14:35 UTC

KRAS G12C LUNG CANCER

Get alerted when new KRAS G12C LUNG CANCER trials appear

Breakthrough trial targets deadly lung cancer mutation with new drug combo